DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia

被引:7
|
作者
Kim, Stephanie S. [1 ]
Lee, Seung Cho [2 ]
Lim, Bumjin [3 ]
Shin, Seung-Ho [2 ]
Kim, Mee Young [6 ]
Kim, Sol-Yi [2 ]
Lim, Hyeyeun [2 ]
Charton, Clementine [1 ]
Shin, Dongho [7 ]
Moon, Hyong Woo [7 ]
Kim, Jinho [1 ]
Park, Donghyun [2 ]
Park, Woong-Yang [2 ,4 ,5 ]
Lee, Ji Youl [6 ,7 ]
机构
[1] Seoul Natl Univ, Precis Med Ctr, Future Innovat Res Div, Bundang Hosp, Seongnam, South Korea
[2] GENINUS Inc, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[4] Samsung Med Ctr, Samsung Genome Inst, Seoul, South Korea
[5] Sungkyunkwan Univ, Dept Mol Cell Biol, Sch Med, Suwon, South Korea
[6] Catholic Univ Korea, Canc Res Inst, Coll Med, Seoul, South Korea
[7] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Urol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Benign prostatic hyperplasia; Biomarkers; Cancer diagnosis; DNA methylation; Enzymatic conversion; Gleason score; Prostate cancer; Target enrichment sequencing;
D O I
10.1016/j.prnil.2023.01.001
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying on the information of the patient's symptoms or levels of prostate-specific antigen. Methods: A total of 42 PCa patients and 11 BPH patients were recruited. Genomic DNA was purified from tissues and used for the library preparation of the target-enriched methylome with enzymatic conversion and a Twist 85 Mbp EM-seq panel. Paired-end sequencing (150 bp) was performed using NovaSeq 6000 or NextSeq 550. After quality control, including adapter trimming and de-duplication of raw sequencing data, differential methylation patterns were analyzed between the BPH and PCa groups. Results: We report DNA methylation patterns existing between BPH and PCa. The major finding is that broad hypermethylation occurred at genic loci in PCa tissues as compared to the BPH. Gene ontology analysis suggested that hypermethylation of genic loci involved in chromatin and transcriptional regulation is involved in cancer progression. We also compared PCa tissues with high Gleason scores to tissues with low Gleason scores. The high-Gleason PCa tissues showed hundreds of focal differentially methylated CpG sites corresponding to genes functioning in cancer cell proliferation or metastasis. This suggests that dissecting early-to-advanced-grade cancer stages requires an in-depth analysis of differential methylation at the single CpG site level. Conclusions: Our study reports that enzymatic methylome sequencing data can be used to distinguish PCa from BPH and advanced PCa from early-stage PCa. The stage-specific methylation patterns in this study will be valuable resources for diagnostic purposes as well as further development of liquid biopsy approaches for the early detection of PCa. (c) 2023 The Asian Pacific Prostate Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:113 / 121
页数:9
相关论文
共 50 条
  • [1] DISTINGUISHING PROSTATE CANCER FROM BENIGN PROSTATIC HYPERPLASIA BY NANODEVICE DETECTION OF BIOMARKERS ASSOCIATED WITH REACTIVE STROMA
    Singer, Elizabeth
    Linehan, Jennifer
    Imam, Ashraf
    Smith, David
    Loera, Sofia
    Wilson, Timothy
    Smith, Steven
    JOURNAL OF UROLOGY, 2012, 187 (04): : E852 - E852
  • [2] Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer
    El Melegy, N. T.
    Aboulella, H. A.
    Abul-Fadl, A. M.
    Mohamed, N. A.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2010, 67 (03) : 109 - 112
  • [3] Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review
    McNally, Christopher J.
    Ruddock, Mark W.
    Moore, Tara
    McKenna, Declan J.
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 5225 - 5241
  • [4] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (03): : F60 - F62
  • [5] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2015, 25 : F82 - F84
  • [6] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2016, 26 (01): : F20 - F22
  • [7] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    BYAR, DP
    LANCET, 1975, 1 (7911): : 866 - 866
  • [8] Benign prostatic hyperplasia, cancer of the prostate
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (02): : F40 - F42
  • [9] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    WILLIAMS, RD
    BLACKARD, CE
    LANCET, 1974, 2 (7891): : 1265 - 1265
  • [10] Benign prostatic Hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2016, 26 (03): : F65 - F66